Kenneth E. Hook

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

David W. Fry, Alexander J. Bridges, William A. Denny et al. · Proceedings of the National Academy of Sciences · 1998 · 418 citations

Life Sciences, Biochemistry, Pharmacology +17

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

Andrea J. Gonzales, Kenneth E. Hook, Irene W. Althaus et al. · Molecular Cancer Therapeutics · 2008 · 221 citations · Full text

Medicine, Oncology, Pharmacology +15

Surgically induced osteoarthritis in the rat results in the development of both osteoarthritis-like joint pain and secondary hyperalgesia

Susan E. Bove, Keith D. Laemont, Rachel M. Brooker et al. · Osteoarthritis and Cartilage · 2006 · 152 citations · Full text

Medicine, Orthopaedic Surgery, Surgery +12

An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

Kenneth E. Hook, Scott J. Garza, Maruja E. Lira et al. · Molecular Cancer Therapeutics · 2012 · 96 citations · Full text

Medicine, Molecular Biology, Pharmacology +17

Binding of 14-3-3beta to the carboxyl terminus of Wee1 increases Wee1 stability, kinase activity, and G2-M cell population.

Ya Wang, C. Jacobs, Kenneth E. Hook et al. · PubMed · 2000 · 92 citations

Life Sciences, Biochemistry, Molecular Biology +16